| Assessment Status | Awaiting HTA submission from Applicant |
| HTA ID | 22065 |
| Drug | Olaparib |
| Brand | Lynparza® |
| Indication | As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 26/10/2022 |
| Rapid review completed | 20/10/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 26/10/2022 |
| Pre-submission consultation with Applicant | 13/12/2022 |
